Travere Therapeutics, Inc. today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its ...
Guggenheim analyst Vamil Divan reiterated a Buy rating on Savara yesterday and set a price target of $11.00. The company’s shares closed yesterday at $5.08. Claim 55% Off TipRan ...
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and ...
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
Quanterix Corporation , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO" ...
New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...
The United States market has shown robust performance, climbing 1.5% in the last week and an impressive 26% over the past year, with earnings projected to grow by 17% annually. In this thriving ...
Over the last 7 days, the United States market has risen by 3.2%, contributing to a remarkable 31% increase over the past ...
Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with ...
Investor's Business Daily on MSN
Why these four biotech stocks prove that follow-on entries still pop up in stock market leaders
AnaptysBio recorded $234 million in sales over the past four quarters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results